Abstract:The TASK-3 channel is a member of the K2P family that is important for the maintenance of the resting membrane potential. Previous studies have demonstrated that the TASK-3 channel is involved in several physiologic and pathologic processes, including sleep/wake control, cognition, and epilepsy. However, there is still a lack of selective pharmacological tools for TASK-3, which limits further research on channel function. In this work, using a high-throughput screen, we discovered that N-(2-((4-nitro-2-(trifluoromethyl)phenyl)amino)ethyl)benzamide (NPBA) showed excellent potency and selectivity as a novel TASK-3 activator. The molecular determinants of NPBA activation were then investigated by combining chimera and mutagenesis analysis. Two distant clusters of residues located at the extracellular end of the second transmembrane domain (A105 and A108) and the intracellular end of the third transmembrane domain (E157) were found to be critical for NPBA activation. We then compared the essentials of the actions of NPBA with inhalation anesthetics that nonselectively activate TASK-3 and found that they may activate TASK-3 channels through different mechanisms. Finally, we transplanted the three residues A105, A108, and E157 into the TASK-1 channel, which resists NPBA activation, and the constructed mutant TASK-1(G105A, V108A, A157E) showed dramatically increased activation by NPBA, confirming the importance of these two distant clusters of residues. SIGNIFICANCE STATEMENT: TASK-3 channels conduct potassium and are involved in various physiological and pathological processes. However, the lack of selective modulators has hindered efforts to increase our understanding of the physiological roles of TASK-3 channels. By using a high-throughput screen, we identified NPBA as a potent and selective TASK-3 activator, and we show that NPBA is a more potent activator than terbinafine, the only reported TASK-3 selective activator to date. We also show here that NPBA has outstanding selectivity for TAS-3 channels. These characteristics make NPBA a promising pharmacological probe for research focused on defining TASK-3 channel function(s). In addition, we identified two distant clusters of residues as determinants of NPBA activation providing new molecular clues for the understanding of the gating mechanism of K2P channels.

Advances in the Understanding of Two-Pore Domain TASK Potassium Channels and Their Potential as Therapeutic Targets

Structures of TASK-1 and TASK-3 K2P channels provide insight into their gating and dysfunction in disease

C-type inactivation and proton modulation mechanisms of the TASK3 channel

Development of Non-opioid Analgesics Targeting Two-pore Domain Potas- sium Channels

A lower X-gate in TASK channels traps inhibitors within the vestibule

Development of Non-opioid Analgesics Targeting Two-pore Domain Potassium Channels

Selective activation of TWIK-related acid-sensitive K + 3 subunit-containing channels is analgesic in rodent models.

Potassium channel TASK-5 forms functional heterodimers with TASK-1 and TASK-3 to break its silence

A Small-Molecule Compound Selectively Activates K2P Channel TASK-3 by Acting at Two Distant Clusters of Residues.

TASK-1 and TASK-3 channels modulate pressure overload-induced cardiac remodeling and dysfunction

Potassium Channels: Structures, Diseases, and Modulators

From Basic Physiology to Clinical Applications

Researches Toward Potassium Channels on Tumor Progressions.

Selective Activation of TASK-3-containing K+ Channels Reveals Their Therapeutic Potentials in Analgesia

Targeting TRP channels: recent advances in structure, ligand binding, and molecular mechanisms

Potassium channels, tumorigenesis and targeted drugs

Design of bisamide inhibitors of the TASK-1 potassium channel in silico

Fine-tuning pH sensor H98 by remote essential residues in the hydrogen-bond network of mTASK-3

Current strategies for the discovery of K+ channel modulators.

The ATP-sensitive potassium channel: a therapeutic target for neurodegeneration?

Voltage-gated potassium channel 1.3: A promising molecular target in multiple disease therapy